All questionsDrug interactions: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer1 question · 2 sourcesDrug interactionsWhat drug interactions does TRODELVY have?“UGT1A1 Inhibitors: Avoid administering UGT1A1 inhibitors with TRODELVY. SN-38 is a UGT1A1 substrate. Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. UGT1A1 Inducers: Avoid administering UGT1A1 inducers with TRODELVY. SN-38 is a UGT1A1 substrate. Concomitant administration of TRODELVY with inducers of UGT1A1 may reduce exposure to SN-38.” (opens the source at this quote in a new tab)CopyFlag“Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite, SN-38” (opens the source at this quote in a new tab)CopyFlag